These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28295165)

  • 1. Declining invasive prenatal diagnostic procedures: A comparison of tertiary hospital and national data from 2012 to 2015.
    Johnson K; Kelley J; Saxton V; Walker SP; Hui L
    Aust N Z J Obstet Gynaecol; 2017 Apr; 57(2):152-156. PubMed ID: 28295165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive prenatal diagnostic practice in Denmark 1996 to 2006.
    Vestergaard CH; Lidegaard Ø; Tabor A
    Acta Obstet Gynecol Scand; 2009; 88(3):362-5. PubMed ID: 19172424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uptake of noninvasive prenatal testing at a large academic referral center.
    Larion S; Warsof SL; Romary L; Mlynarczyk M; Peleg D; Abuhamad AZ
    Am J Obstet Gynecol; 2014 Dec; 211(6):651.e1-7. PubMed ID: 24954652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prenatal screening for fetal aneuploidy in singleton pregnancies.
    Chitayat D; Langlois S; Douglas Wilson R; ;
    J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population-based trends in invasive prenatal diagnosis for ultrasound-based indications: two decades of change from 1994 to 2016.
    Lostchuck E; Poulton A; Halliday J; Hui L
    Ultrasound Obstet Gynecol; 2019 Apr; 53(4):503-511. PubMed ID: 29877030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chorionic villus sampling in the cell-free DNA aneuploidy screening era: careful selection criteria can maximise the clinical utility of screening and invasive testing.
    Kane SC; Reidy KL; Norris F; Nisbet DL; Kornman LH; Palma-Dias R
    Prenat Diagn; 2017 Apr; 37(4):399-408. PubMed ID: 28207933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuchal translucency and the acceptance of invasive prenatal chromosomal diagnosis in women aged 35 and older.
    Zoppi MA; Ibba RM; Putzolu M; Floris M; Monni G
    Obstet Gynecol; 2001 Jun; 97(6):916-20. PubMed ID: 11384696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in prenatal screening and diagnostic testing among women referred for advanced maternal age.
    Nakata N; Wang Y; Bhatt S
    Prenat Diagn; 2010 Mar; 30(3):198-206. PubMed ID: 20063323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. National decline in invasive prenatal diagnostic procedures in association with uptake of combined first trimester and cell-free DNA aneuploidy screening.
    Robson SJ; Hui L
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):507-10. PubMed ID: 26259499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study.
    Tabor A; Vestergaard CH; Lidegaard Ø
    Ultrasound Obstet Gynecol; 2009 Jul; 34(1):19-24. PubMed ID: 19504504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is nuchal translucency screening associated with different rates of invasive testing in an older obstetric population?
    Chasen ST; McCullough LB; Chervenak FA
    Am J Obstet Gynecol; 2004 Mar; 190(3):769-74. PubMed ID: 15042012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ultrasound screening for Down syndrome and other chromosomal abnormalities by fetal nuchal translucency measurement between 11-14 weeks of gestation].
    Dimitrova V; Markov D; Chernev T; Karag'ozova Zh; Mazneĭkova V; Andonova S; Vŭzharova R
    Akush Ginekol (Sofiia); 2005; 44(1):32-7. PubMed ID: 15853009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of utilization of early aneuploidy screening on amniocenteses available for training in obstetrics and fetal medicine.
    Rose NC; Lagrave D; Hafen B; Jackson M
    Prenat Diagn; 2013 Mar; 33(3):242-4. PubMed ID: 23354826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the utilization of prenatal diagnosis.
    Benn PA; Egan JF; Fang M; Smith-Bindman R
    Obstet Gynecol; 2004 Jun; 103(6):1255-60. PubMed ID: 15172861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Contribution of array CGH in the management of fetal nuchal translucency].
    Beal J; Jedraszak G; Saliou AH; Copin H; Sergent F; Gondry J; Merviel P; Muszynski C
    Gynecol Obstet Fertil Senol; 2020 Feb; 48(2):174-180. PubMed ID: 31634590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging issues in invasive prenatal diagnosis: Safety and competency in the post-NIPT era.
    Hui L; The S; McCarthy EA; Walker SP
    Aust N Z J Obstet Gynaecol; 2015 Dec; 55(6):541-6. PubMed ID: 26303213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective exploratory study of fetal genetic invasive procedures at a University Hospital.
    Andrew C; Koshy T; Gopal S; Paul SFD
    J Obstet Gynaecol; 2018 Oct; 38(7):906-910. PubMed ID: 29553859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population-based trends in prenatal screening and diagnosis for aneuploidy: a retrospective analysis of 38 years of state-wide data.
    Hui L; Muggli EE; Halliday JL
    BJOG; 2016 Jan; 123(1):90-7. PubMed ID: 26108969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chorionic villus needle sampling by the transabdominal route or by placental centesis. A series of 930 cases].
    Guidicelli B; Levy A; Piquet C; Gamerre M
    J Gynecol Obstet Biol Reprod (Paris); 1993; 22(8):851-5. PubMed ID: 8132961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the utilization of invasive prenatal diagnosis in The Netherlands during 2000-2009.
    Lichtenbelt KD; Alizadeh BZ; Scheffer PG; Stoutenbeek P; Schielen PC; Page-Christiaens LC; Schuring-Blom GH
    Prenat Diagn; 2011 Aug; 31(8):765-72. PubMed ID: 21692084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.